13

SENATE BILL 410

57th Legislature - STATE OF NEW MEXICO - FIRST SESSION, 2025

INTRODUCED BY

Craig W. Brandt

5

1

2

3

6 7

8

9

10

11 12

14

15

16

17

18

19

20

21

22

23

24

25

AN ACT

RELATING TO CONTROLLED SUBSTANCES; RESCHEDULING CRYSTALLINE POLYMORPH PSILOCYBIN IN ACCORDANCE WITH FEDERAL LAW.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF NEW MEXICO:

SECTION 1. Section 30-31-3 NMSA 1978 (being Laws 1972, Chapter 84, Section 3, as amended) is amended to read:

"30-31-3. DUTY TO ADMINISTER. --

The board shall administer the Controlled Substances Act and may add by regulation substances to the list of substances enumerated in Schedules I through IV pursuant to the procedures of the Uniform Licensing Act. In determining whether a substance has the potential for abuse, the board shall consider the following:

(1) the actual or relative abuse of the substance;

.230577.1ms

.230577.1ms

1

2

| 3 | (3) the state of current scientific knowledge |
|----|---|
| 4 | regarding the substance; |
| 5 | (4) the history and current pattern of abuse; |
| 6 | (5) the scope, duration and significance of |
| 7 | abuse; |
| 8 | (6) the risk to the public health; and |
| 9 | (7) the potential of the substance to produce |
| 10 | psychic or physiological dependence liability. |
| 11 | B. After considering the factors enumerated in |
| 12 | Subsection A of this section, the board shall make findings and |
| 13 | issue regulations controlling the substance if it finds the |
| 14 | substance has a potential for abuse. |
| 15 | C. If any substance is designated as a controlled |
| 16 | substance under federal law and notice is given to the board, |
| 17 | the board may, by regulation, similarly control the substance |
| 18 | under the Controlled Substances Act after providing for a |
| 19 | hearing pursuant to the Uniform Licensing Act. |
| 20 | D. Authority to control under this section does not |
| 21 | extend to distilled spirits, wine, malt beverages, tobacco or |
| 22 | pesticides as defined in the Pesticide Control Act. |
| 23 | E. Notwithstanding Subsection C of this section, |
| 24 | immediately upon rescheduling by the United States food and |
| 25 | 1 1 |

(2)

pharmacological effect of the substance, if known;

the scientific evidence of the

| 1 | crystalline polymorph psilocybin, shall be scheduled and listed | | | | | | | | | |
|----|---|--|--|--|--|--|--|--|--|--|
| 2 | in a manner to coincide with federal law, including the | | | | | | | | | |
| 3 | Controlled Substances Act public law 91-513, 84 Stat. 1236, 21 | | | | | | | | | |
| 4 | U.S.C. Section 801 et seq." | | | | | | | | | |
| 5 | SECTION 2. Section 30-31-6 NMSA 1978 (being Laws 1972, | | | | | | | | | |
| 6 | Chapter 84, Section 6, as amended) is amended to read: | | | | | | | | | |
| 7 | "30-31-6. SCHEDULE IThe following controlled | | | | | | | | | |
| 8 | substances are included in Schedule I: | | | | | | | | | |
| 9 | A. any of the following opiates, including their | | | | | | | | | |
| 10 | isomers, esters, ethers, salts and salts of isomers, esters and | | | | | | | | | |
| 11 | ethers, unless specifically exempted, whenever the existence of | | | | | | | | | |
| 12 | these isomers, esters, ethers and salts is possible within the | | | | | | | | | |
| 13 | specific chemical designation: | | | | | | | | | |
| 14 | (1) acetylmethadol; | | | | | | | | | |
| 15 | (2) allylprodine; | | | | | | | | | |
| 16 | (3) alphacetylmethadol; | | | | | | | | | |
| 17 | (4) alphameprodine; | | | | | | | | | |
| 18 | (5) alphamethadol; | | | | | | | | | |
| 19 | (6) benzethidine; | | | | | | | | | |
| 20 | (7) betacetylmethadol; | | | | | | | | | |
| 21 | (8) betameprodine; | | | | | | | | | |
| 22 | (9) betamethadol; | | | | | | | | | |
| 23 | (10) betaprodine; | | | | | | | | | |
| 24 | (11) clonitazene; | | | | | | | | | |
| 25 | (12) dextromoramide; | | | | | | | | | |
| | | | | | | | | | | |

| 1 | (13) | dextrorphan; |
|----|------|-------------------------|
| 2 | (14) | diampromide; |
| 3 | (15) | diethylthiambutene; |
| 4 | (16) | dimenoxadol; |
| 5 | (17) | dimepheptanol; |
| 6 | (18) | dimethylthiambutene; |
| 7 | (19) | dioxaphetyl butyrate; |
| 8 | (20) | dipipanone; |
| 9 | (21) | ethylmethylthiambutene; |
| 10 | (22) | etonitazene; |
| 11 | (23) | etoxeridine; |
| 12 | (24) | furethidine; |
| 13 | (25) | hydroxypethidine; |
| 14 | (26) | ketobemidone; |
| 15 | (27) | levomoramide; |
| 16 | (28) | levophenacylmorphan; |
| 17 | (29) | morpheridine; |
| 18 | (30) | noracymethadol; |
| 19 | (31) | norlevorphanol; |
| 20 | (32) | normethadone; |
| 21 | (33) | norpipanone; |
| 22 | (34) | phenadoxone; |
| 23 | (35) | phenampromide; |
| 24 | (36) | phenomorphan; |
| 25 | (37) | phenoperidine; |

| 1 | (38) princiamide; |
|----|--|
| 2 | (39) proheptazine; |
| 3 | (40) properidine; |
| 4 | (41) racemoramide; and |
| 5 | (42) trimeperidine; |
| 6 | B. any of the following opium derivatives, their |
| 7 | salts, isomers and salts of isomers, unless specifically |
| 8 | exempted, whenever the existence of these salts, isomers and |
| 9 | salts of isomers is possible within the specific chemical |
| 10 | designation: |
| 11 | (1) acetorphine; |
| 12 | (2) acetyldihydrocodeine; |
| 13 | (3) benzylmorphine; |
| 14 | (4) codeine methylbromide; |
| 15 | (5) codeine-N-oxide; |
| 16 | (6) cyprenorphine; |
| 17 | (7) desomorphine; |
| 18 | (8) dihydromorphine; |
| 19 | (9) etorphine; |
| 20 | (10) heroin; |
| 21 | (11) hydromorphinol; |
| 22 | (12) methyldesorphine; |
| 23 | (13) methyldihydromorphine; |
| 24 | (14) morphine methylbromide; |
| 25 | (15) morphine methylsulfonate; |
| | |

| 1 | (16) morphine-N-oxide; | | | | | | | | |
|----|---|--|--|--|--|--|--|--|--|
| 2 | (17) myrophine; | | | | | | | | |
| 3 | (18) nicocodeine; | | | | | | | | |
| 4 | (19) nicomorphine; | | | | | | | | |
| 5 | (20) normorphine; | | | | | | | | |
| 6 | (21) pholcodine; and | | | | | | | | |
| 7 | (22) thebacon; | | | | | | | | |
| 8 | C. any material, compound, mixture or preparation | | | | | | | | |
| 9 | that contains any quantity of the following hallucinogenic | | | | | | | | |
| 10 | substances, their salts, isomers and salts of isomers, unless | | | | | | | | |
| 11 | specifically exempted, whenever the existence of these salts, | | | | | | | | |
| 12 | isomers and salts of isomers is possible within the specific | | | | | | | | |
| 13 | chemical designation: | | | | | | | | |
| 14 | (1) 3,4-methylenedioxy amphetamine; | | | | | | | | |
| 15 | (2) 5-methoxy-3,4-methylenedioxy amphetamine; | | | | | | | | |
| 16 | (3) 3,4,5-trimethoxy amphetamine; | | | | | | | | |
| 17 | (4) bufotenine; | | | | | | | | |
| 18 | (5) diethyltryptamine; | | | | | | | | |
| 19 | (6) dimethyltryptamine; | | | | | | | | |
| 20 | (7) 4-methyl-2,5-dimethoxy amphetamine; | | | | | | | | |
| 21 | (8) ibogaine; | | | | | | | | |
| 22 | (9) lysergic acid diethylamide; | | | | | | | | |
| 23 | (10) mescaline; | | | | | | | | |
| 24 | (11) peyote, except as otherwise provided in | | | | | | | | |
| 25 | the Controlled Substances Act; | | | | | | | | |
| | .230577.1ms | | | | | | | | |

```
1
                        (12)
                              N-ethyl-3-piperidyl benzilate;
 2
                        (13)
                              N-methyl-3-piperidyl benzilate;
 3
                        (14)
                              psilocybin;
 4
                        (15)
                              psilocyn;
 5
                              synthetic cannabinoids, including:
                        (16)
 6
                              (a)
                                   1-[2-(4-(morpholiny1)ethy1]
 7
       -3-(1-naphthoy1)indole;
 8
                                   1-buty1-3-(1-napthoy1)indole;
                              (b)
 9
                              (c)
                                   1-hexy1-3-(1-naphthoy1)indole;
10
                              (d)
                                   1-penty1-3-(1-naphthoy1)indole;
                                   1-penty1-3-(2-methoxyphenylacety1)
11
                              (e)
12
       indole;
13
                              (f)
                                   cannabicyclohexanol (CP 47, 497 and
14
      homologues: 5-(1,1-dimethylheptyl)-2-[(1R,3S)
15
       -3-hydroxycyclohexyl]-phenol (CP-47,497); and 5-(1,
16
       1-dimethyloctyl)-2-[(lR,3S)-3-hydroxycyclohexyl]-phenol;
17
                              (g) 6aR, 10aR) - 9 - (hydroxymethy1)
18
       -6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,
19
       10a-tetrahydrobenzo[c]chromen-1-o1);
20
                                   dexanabinol, (6aS, 10aS)
                              (h)
21
       -9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
22
       -6a,7,10,10a-tetrahydrobenzo[c]chromen-l-ol;
23
                                   1-penty1-3-(4-chloro naphthoy1)
                              (i)
24
       indole;
25
                              (i)
                                   (2-methyl-1-propyl-1H-indol-3-yl)
       .230577.1ms
```

| • | | |
|---|--|--|
| | | |
| | | |
| | | |
| • | | |

| -1-naphthalenyl-methar | none; | and |
|------------------------|-------|-------------------------------------|
| | (k) | 5-(1,1-dimethylheptyl)-2-(3-hydroxy |
| cyclohexyl)-phenol; | | |
| (17) | 3,4- | methylenedioxymethcathinone; |
| (18) | 3,4- | methylenedioxypyrovalerone; |
| (19) | 4-me | thylmethcathinone; |
| (20) | 4-me | thoxymethcathinone; |
| (21) | 3-f1 | uoromethcathinone; and |
| | | |

(22)

D. the enumeration of peyote as a controlled substance does not apply to the use of peyote in bona fide religious ceremonies by a bona fide religious organization, and members of the organization so using peyote are exempt from registration. Any person who manufactures peyote for or distributes peyote to the organization or its members shall comply with the federal Comprehensive Drug Abuse Prevention and Control Act of 1970 and all other requirements of law;

4-fluoromethcathinone;

- E. the enumeration of Schedule I controlled substances does not apply to:
- (1) hemp pursuant to rules promulgated by the board of regents of New Mexico state university on behalf of the New Mexico department of agriculture;
- (2) cultivation of hemp by persons pursuant to rules promulgated by the board of regents of New Mexico state university on behalf of the New Mexico department of .230577.lms

agriculture;

derivatives of tetrahydrocannabinols, including tetrahydrocannabinols or chemical derivatives of tetrahydrocannabinols or chemical derivatives of tetrahydrocannabinols with concentrations of up to five percent as measured using a post-decarboxylation method and based on percentage dry weight, possessed by a person in connection with the cultivation, transportation, testing, researching, manufacturing or other processing of the plant Cannabis sativa L., or any part of the plant whether growing or not, if authorized pursuant to rules promulgated, pursuant to the Hemp Manufacturing Act, by the board of regents of New Mexico state university on behalf of the New Mexico department of agriculture or the department of environment; or

derivatives of tetrahydrocannabinols, including tetrahydrocannabinols or chemical derivatives of tetrahydrocannabinols or chemical derivatives of tetrahydrocannabinols in any concentration possessed by a person in connection with the extraction of tetrahydrocannabinols or chemical derivatives of tetrahydrocannabinols, if authorized pursuant to rules promulgated, pursuant to the Hemp Manufacturing Act, by the board of regents of New Mexico state university on behalf of the New Mexico department of agriculture or the department of environment; [and]

.230577.1ms

| 2 |
|----|
| 3 |
| 4 |
| 5 |
| 6 |
| 7 |
| 8 |
| 9 |
| 10 |
| 11 |
| 12 |
| 13 |
| 14 |
| 15 |
| 16 |
| 17 |
| 18 |
| 19 |
| 20 |
| 21 |
| 22 |
| 23 |
| 24 |
| 25 |

1

| |] | F. | cont | rolled | substance | es a | added | to | Schedule | e I | by |
|-------|------------|------|------|--------|-----------|------|-------|-----|----------|-----|----|
| rule | adopte | d by | the | board | pursuant | to | Sect | Lon | 30-31-3 | NM | SA |
| 1978; | <u>and</u> | | | | | | | | | | |

G. psilocybin except immediately upon its

rescheduling by the United Stated food and drug administration

of the pharmaceutical composition of crystalline polymorph

psilocybin."

- 10 -